Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus
Study of Neonatal Immunoglobulin G (IgG) Fc Receptor (FcRn) Expression in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT): Implication in the Pathophysiology of Systemic Lupus
University Hospital, Tours
50 participants
Jul 21, 2023
OBSERVATIONAL
Conditions
Summary
This study evaluates the variation of expression of the neonatal Fc receptor (FcRn) in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT) and monocytes along with the surface expression of Fc gamma type II receptor (RII) and RIII in active or newly diagnosed lupus patients compared to inactive lupus patients.
Eligibility
Inclusion Criteria5
- Age ≥ 18 years
- Diagnosis of definite systemic lupus which may be associated with secondary antiphospholipid syndrome and/or secondary Gougerot-Sjögren's
- Lupus patient, newly diagnosed or known, untreated or in relapse
- Lupus patient considered stable by the treating practitioner
- Requiring blood sampling for follow-up
Exclusion Criteria3
- Main autoimmune disease other than lupus
- Patient under legal protection, guardianship or curators
- Opposition to data processing
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Three extra tubes of blood will be taken at each consultation or inpatient visit when routine blood samples are taken as part of lupus monitoring.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05859191